Paul Workman

List of Publications by Year
in descending order

83 papers	11,353 citations	44069 48 h-index	56724 83 g-index
90 all docs	90 docs citations	90 times ranked	17158 citing authors

#	Article	IF	Citations
1	Target 2035 â€“ update on the quest for a probe for every protein. RSC Medicinal Chemistry, 2022, 13, 13-21.	3.9	39
2	Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patients. Drug Discovery Today, 2022, 27, 946-950.	6.4	1
3	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2021, 49, D1074-D1082.	14.5	63
4	Public resources for chemical probes: the journey so far and the road ahead. Future Medicinal Chemistry, 2021, 13, 731-747.	2.3	24
5	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nature Reviews Clinical Oncology, 2021, 18, 454-467.	27.6	11
6	A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. Trends in Pharmacological Sciences, 2021, 42, 313-315.	8.7	16
7	Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3.	5.2	13
8	HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 2021, 81, 6207-6218.	0.9	25
9	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	12.8	10
10	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	7.3	30
11	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports, 2020, 10, 16000.	3.3	8
12	Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE, 2020, 15, e0234103.	2.5	50
13	The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585.	3.3	68
14	From patent to patient: analysing access to innovative cancer drugs. Drug Discovery Today, 2020, 25, 1561-1568.	6.4	11
15	Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective. Advances in Experimental Medicine and Biology, 2020, 1243, 163-179.	1.6	18
16	CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells. Cancer Research, 2020, 80, 1735-1747.	0.9	38
17	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	8.2	40
18	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 2019, 38, 5905-5920.	5.9	23

#	Article	IF	Citations
19	Transforming cancer drug discovery with Big Data and AI. Expert Opinion on Drug Discovery, 2019, 14, 1089-1095.	5.0	22
20	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research, 2019, 25, 4624-4633.	7.0	21
21	Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene, 2019, 38, 5076-5090.	5.9	26
22	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2019, 47, D917-D922.	14.5	75
23	Structural and functional characterisation of human RNA helicase DHX8 provides insights into the mechanism of RNA-stimulated ADP release. Biochemical Journal, 2019, 476, 2521-2543.	3.7	6
24	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	12.6	1,199
25	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	21.4	182
26	Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chemical Biology, 2018, 25, 194-205.e5.	5.2	71
27	Molecular profiling and combinatorial activity of <scp>CCT</scp>068127: a potent <scp>CDK</scp>2 and <scp>CDK</scp>9 inhibitor. Molecular Oncology, 2018, 12, 287-304.	4.6	33
28	Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). Journal of Medicinal Chemistry, 2018, 61, 918-933.	6.4	81
29	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	1.3	94
30	Privileged Structures and Polypharmacology within and between Protein Families. ACS Medicinal Chemistry Letters, 2018, 9, 1199-1204.	2.8	16
31	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 2017, 66, 1268-1277.	12.1	75
32	Inhibitors of cyclin-dependent kinases as cancer therapeutics. , 2017, 173, 83-105.		278
33	How Much Longer Will We Put Up With $100,000 Cancer Drugs?. Cell, 2017, 168, 579-583.	28.9	74
34	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. Cancer Cell, 2017, 32, 9-25.	16.8	183
35	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	6.4	47
36	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current Pharmaceutical Design, 2017, 22, 6935-6945.	1.9	65

#	Article	IF	Citations
37	Structure-based drug design: aiming for a perfect fit. Essays in Biochemistry, 2017, 61, 431-437.	4.7	75
38	Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. ELife, 2016, 5, .	6.0	69
39	2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. ACS Medicinal Chemistry Letters, 2016, 7, 573-578.	2.8	39
40	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. Cancer Research, 2016, 76, 2731-2742.	0.9	79
41	Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70. Journal of Medicinal Chemistry, 2016, 59, 4625-4636.	6.4	29
42	Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology, 2016, 43, 436-445.	2.2	64
43	Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery, 2016, 15, 699-718.	46.4	111
44	The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. Drug Discovery Today: Disease Models, 2016, 21, 23-32.	1.2	8
45	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. MedChemComm, 2016, 7, 1580-1586.	3.4	19
46	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. Journal of Medicinal Chemistry, 2016, 59, 1078-1101.	6.4	89
47	Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, 2016, 7, 3658-3661.	1.8	11
48	Distinctive Behaviors of Druggable Proteins in Cellular Networks. PLoS Computational Biology, 2015, 11, e1004597.	3.2	43
49	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Panâ€“Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 77-86.	7.0	265
50	Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. Journal of Medicinal Chemistry, 2015, 58, 1717-1735.	6.4	65
51	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	8.0	698
52	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology, 2015, 11, 973-980.	8.0	114
53	Maximizing the Therapeutic Potential of HSP90 Inhibitors. Molecular Cancer Research, 2015, 13, 1445-1451.	3.4	161
54	Drugging cancer genomes. Nature Reviews Drug Discovery, 2013, 12, 889-890.	46.4	47

#	Article	IF	Citations
55	A public-private partnership to unlock the untargeted kinome. Nature Chemical Biology, 2013, 9, 3-6.	8.0	141
56	Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50.	46.4	111
57	ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nature Chemical Biology, 2013, 9, 307-312.	8.0	132
58	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget, 2013, 4, 1647-1661.	1.8	20
59	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology, 2012, 52, 549-573.	9.4	96
60	Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?. Clinical Cancer Research, 2012, 18, 64-76.	7.0	855
61	Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 2012, 30, 679-692.	17.5	883
62	HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discovery Today, 2012, 17, 242-252.	6.4	101
63	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 6949-6965.	3.0	31
64	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 1561-1570.	7.0	178
65	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discovery Today, 2010, 15, 88-97.	6.4	69
66	Probing the Probes: Fitness Factors For Small Molecule Tools. Chemistry and Biology, 2010, 17, 561-577.	6.0	253
67	Envisioning the future of early anticancer drug development. Nature Reviews Cancer, 2010, 10, 514-523.	28.4	262
68	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research, 2010, 70, 5963-5973.	0.9	96
69	Drugging the heat shock factor 1 pathway: Exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell Cycle, 2009, 8, 3806-3808.	2.6	35
70	Death by chaperone: HSP90, HSP70 or both?. Cell Cycle, 2009, 8, 518-526.	2.6	93
71	Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular Cancer Therapeutics, 2009, 8, 1725-1738.	4.1	253
72	Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis. Cancer Cell, 2008, 14, 250-262.	16.8	291

#	Article	IF	Citations
73	4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 196-218.	6.4	386
74	NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research, 2008, 68, 2850-2860.	0.9	433
75	Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Molecular Cancer Therapeutics, 2007, 6, 1198-1211.	4.1	141
76	In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. Cancer Research, 2007, 67, 2206-2216.	0.9	111
77	Using biomarkers in drug development. Clinical Advances in Hematology and Oncology, 2006, 4, 736-9.	0.3	5
78	The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3338-3343.	2.2	228
79	Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies. Journal of Clinical Oncology, 2005, 23, 4152-4161.	1.6	479
80	Novel, Potent Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based Design. Journal of Medicinal Chemistry, 2005, 48, 4212-4215.	6.4	232
81	The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway. Cancer Research, 2004, 64, 262-272.	0.9	187
82	How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development. Current Pharmaceutical Design, 2003, 9, 891-902.	1.9	141
83	Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Molecular Cancer Therapeutics, 2003, 2, 131-8.	4.1	63